Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02621593 · ClinicalTrials.gov registry record · NA

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

A NA study of Dry Eye Syndromes, sponsored by Lumenis Be.

Completed
Registry status
NA
Development phase
44
Enrollment target
2
Study locations

NCT02621593 is a NA study of Dry Eye Syndromes that has completed, run by Lumenis Be. The registered enrollment target is 44 participants, below the 412-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02621593, a NA study of Dry Eye Syndromes, has completed, sponsored by Lumenis Be.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to pre-treatment.

Conditions Studied

Dry Eye Syndromes

Interventions

  • DEVICE M22-IPL

Study Locations (2)

California

  • Gaster Eye Center - Beverly Hills

Texas

  • Dell Laser Consultants - Austin

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2015-10
Est. Completion 2017-01
Phase NA

Sponsor

Lumenis Be

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02621593

The ClinicalTrials.gov registry entry for NCT02621593 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (89% lower). The listed sponsor is Lumenis Be, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 1 intervention - of which M22-IPL is the first listed.

NCT02621593 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT02621593 about?

NCT02621593 is a clinical study titled "Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD". The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to pre-treatment.

What is the current status of trial NCT02621593?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2015-10. Estimated completion is 2017-01.

What conditions does trial NCT02621593 study?

This clinical trial studies the following conditions: Dry Eye Syndromes.

What interventions are being tested in trial NCT02621593?

The interventions under investigation include: M22-IPL (DEVICE).

Who is sponsoring clinical trial NCT02621593?

This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02621593 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dry Eye Syndromes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.